- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07235280
Évaluation de l'innocuité du dapagliflozine avant la chirurgie pour le traitement des patients atteints d'adénocarcinome pulmonaire de stade IA
Étude pilote ouverte sur la sécurité et la tolérance de la dapagliflozine dans l'adénocarcinome pulmonaire de stade IA
This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
PRIMARY OBJECTIVE:
I. To assess safety and tolerability of administering 30 days of neoadjuvant dapagliflozin propanediol (dapagliflozin) before surgery in subjects with stage Ia lung adenocarcinoma.
SECONDARY OBJECTIVE:
I. To measure the effects of dapagliflozin on tumor cell proliferation in lung adenocarcinoma.
EXPLORATORY OBJECTIVES:
I. To measure the effects of neoadjuvant dapagliflozin on biological and metabolic parameters.
II. To measure the effects of neoadjuvant dapagliflozin on biomarkers.
OUTLINE:
Patients receive dapagliflozin orally (PO) once daily (QD) for 30 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT)-guided biopsy on study and collection of blood and urine samples throughout the study.
After completion of study treatment, patients are followed up between days 64 and 72.
Type d'étude
Inscription (Estimé)
Phase
- Première phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tina Tieu
- Numéro de téléphone: 310-633-8400
- E-mail: TinaTieu@mednet.ucla.edu
Sauvegarde des contacts de l'étude
- Nom: Amanda R. Gonzalez
- Numéro de téléphone: 310-794-4376
- E-mail: rngonzalez@mednet.ucla.edu
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- Tina Tieu
- Numéro de téléphone: 310-633-8400
- E-mail: TinaTieu@mednet.ucla.edu
-
Contact:
- Amanda Gonzalez
- Numéro de téléphone: 310-794-4376
- E-mail: rngonzalez@mednet.ucla.edu
-
Chercheur principal:
- Claudio Scafoglio, MD/PhD
-
Chercheur principal:
- Jane Yanagawa, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Must be able to provide written informed consent
- Male or female ≥ 22 years of age at visit 1
- Histologically confirmed stage Ia lung adenocarcinoma, with availability of biopsy tissue for Ki-67 determination
- Planning to undergo surgery for lung adenocarcinoma
- Willing and able to receive a research CT-guided lung biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Leukocytes ≥ 3.0 K/mm^3
- Absolute neutrophil count ≥ 1.5 K/mm^3
- Platelets ≥ 100 K/mm^3
- Total bilirubin ≤ 2 mg/dl
- Aspartate aminotransferase (AST) ≤ 62 IU/L
- Alanine aminotransferase (ALT) ≤ 70 IU/L
- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2
- Diabetic status: diabetic subjects who are not currently receiving treatment will be included in the study. Diabetic subjects who are under treatment with insulin or oral anti-diabetic drugs will be enrolled under observation by endocrinologists on the team, to adjust the dose of the standard of care diabetic drugs to prevent hypoglycemia
- Females of child-bearing potential must have a negative pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must agree to avoid pregnancy during the study and omit to abstinence from heterosexual intercourse or agree to use two methods of birth control (one highly effective method and one additional effective method) at least 4 weeks before the start of protocol therapy
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. Women of child-bearing age will receive a urine pregnancy test to confirm eligibility
- Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study
- Current or previous treatment with SGLT2 inhibitors
- History of other malignancies with exception of malignancies for which all treatment was completed at least 2 years before registration with no evidence of disease and locally treated skin squamous or basal cell carcinoma
- Currently receiving any other investigational agents
- Currently receiving regularly scheduled systemic steroids in the form of prednisone or dexamethasone (more than 10 mg prednisone daily or equivalent). Topical steroid ointments or creams for occasional skin rash is allowed
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, ketoacidosis, severe kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73m^2)
- Subjects with HIV are eligible unless their cluster of differentiation 4 (CD4+) T-cell counts are < 350 cells/µL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective antiretroviral therapy (ART) according to Department of Health and Human Services (DHHS) treatment guidelines is recommended
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (dapagliflozin)
Patients receive dapagliflozin PO QD for 30 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT-guided biopsy on study and collection of blood and urine samples throughout the study. |
Ancillary studies Undergo collection of blood and urine samples
Autres noms:
Undergo CT-guided biopsy
Autres noms:
Given PO
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of adverse events
Délai: Up to day 64-72
|
Will be measured by frequency and severity of toxicities related to dapagliflozin per Common Terminology Criteria for Adverse Events version 6.0. Data will be summarized. Adverse events, severe adverse events, and adverse drug reactions will be coded by body system and Medical Dictionary for Regulatory Activities classification term. Adverse events will be tabulated and will include the number of patients for whom the event occurred, the rate of occurrence, and the severity and relationship to study drug. |
Up to day 64-72
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Tumor cell proliferation change
Délai: From biopsy to surgery up to day 64-72
|
Tumor cell proliferation change will be measured by percentage of Ki-67-positive cells at 3 separate timepoints: 1. pre-treatment archival tissue of standard of care diagnostic lung biopsy samples; 2. pre-treatment research computed tomography-guided lung biopsy; 3. post-treatment archival tissue from the standard of care lung tissue sample from the surgical resection. Will utilize mixed effect negative binomial regression models to compare the Ki-67 in pre- versus post-investigational study drug treatment lung biopsy samples. The outcome in these models will be the number of Ki-67 positive cells in the lung biopsy. The primary inference for the efficacy of the treatment will be the time effect in the model which will test whether the rate of Ki-67 positivity changes is due to the treatment. |
From biopsy to surgery up to day 64-72
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Claudio Scafoglio, MD/PhD, UCLA / Jonsson Comprehensive Cancer Center
- Chercheur principal: Jane Yanagawa, MD, UCLA / Jonsson Comprehensive Cancer Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome
- Adénocarcinome du poumon
- Tumeurs pulmonaires
- Techniques d'investigation
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Manipulation des échantillons
- dapagliflozine
Autres numéros d'identification d'étude
- 25-1048
- NCI-2025-07570 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .